Characterization of TP53 mutations in Pap test DNA of women with and without serous ovarian carcinoma
Jeffrey D. Krimmel‐Morrison(University of Washington), Rosa Ana Risques(University of Washington), Daniela Nachmanson, Barbara M. Norquist(University of Washington), Talayeh Ghezelayagh(University of Washington), Marc R. Radke(University of Washington), Shenyi Lian(University of Washington), Mary J. Emond(Seattle Pacific University), Elizabeth M. Swisher(University of Washington), Enna Hun(University of Washington), Kathryn T. Baker(University of Washington), Jeanne Fredrickson(University of Washington), Yuezheng Zhang(Chinese Academy of Sciences)
Cited by 23
Related Papers
Telomere-to-telomere assembly of a complete human X chromosome
|Nature|2020|842
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017
|Journal of the National Comprehensive Cancer Network|2016|660
Genetic/Familial High-Risk Assessment: Breast and Ovarian
|Journal of the National Comprehensive Cancer Network|2010|650
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
|Annals of Oncology|2020|478
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
|Nature Communications|2020|342